EU extends approval of Prevnar 13 (Pfizer) to young with SCD
The EU has extended approved for the use of Prevenar 13, from Pfizer, in preterm infants, children and adolescents with sickle cell disease who were earlier treated with the 23-valent pneumococcal polysaccharide vaccine. The label also indicates the usage of the vaccine in adults with human immunodeficiency virus (HIV) infection who were earlier treated with the 23-valent pneumococcal polysaccharide vaccine.
In July, the EU extended approval for the vaccine to adults aged 18-49 following Phase III trials. The FDA is currently reviewing the data from these trials.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins